Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Madame Bioscience PCL has the GF Score of 21, which implies that the company
might have
Worst future performance potential, or not enough data.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes Madame Bioscience PCL
might have
Worst future performance potential, or not enough data.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
Madame Bioscience PCL GF Score Related Terms
BKK:MADAME vs KHC, GIS: GF Score Comparison
For the Packaged Foods subindustry, Madame Bioscience PCL's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Madame Bioscience PCL GF Score vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Madame Bioscience PCL's GF Score distribution charts can be found below:
* The bar in red indicates where Madame Bioscience PCL's GF Score falls into.
Madame Bioscience PCL (BKK:MADAME) has a GF Score of 21 as of Jul. 22, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Madame Bioscience PCL and its competitors. This is 58% below median its historical median of 50.00. Over the past decade, Madame Bioscience PCL's GF Score has ranged from 17.00 to 80.00.
Is Madame Bioscience PCL's GF Score too high?
Madame Bioscience PCL's current GF Score of 21 is 58% below median its 10-year median of 50.00. Over the past 10 years, this metric has ranged from a low of 17.00 to a high of 80.00. Overall, Madame Bioscience PCL has a GF Score™ of 21/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Madame Bioscience PCL's GF Score compare to KHC and GIS?
Madame Bioscience PCL's GF Score of 21 can be compared against companies in the Consumer Packaged Goods industry. Historically, Madame Bioscience PCL's own GF Score has ranged from 17.00 to 80.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Consumer Packaged Goods company?
A good GF Score depends on the Consumer Packaged Goods industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on Madame Bioscience PCL and its competitors. Madame Bioscience PCL's current GF Score is 21, which is 58% below median its own 10-year median of 50.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madame Bioscience PCL stock overvalued right now?
Based on GuruFocus' analysis, Madame Bioscience PCL (BKK:MADAME) is currently considered Fairly Valued. The stock's GF Value™ is ฿0.64, compared to a current price of ฿0.66 — trading 3.1% above its estimated fair value. The current GF Score is 21, which is 58% below median its 10-year median of 50.00. Madame Bioscience PCL's overall GF Score™ is 21/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For Madame Bioscience PCL (BKK:MADAME), the current GF Score is 21 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Madame Bioscience PCL (BKK:MADAME) Overvalued in 2026?
Based on GuruFocus' analysis, Madame Bioscience PCL stock appears to be overvalued.
The current stock price of ฿0.66 is trading 3.1% above its estimated GF Value™ of ฿0.64.
GuruFocus considers Madame Bioscience PCL to be Fairly Valued.
Key valuation signals for BKK:MADAME:
GF Score: 21 (58% below median its 10-year median of 50.00)
GF Value™: ฿0.64 vs. price of ฿0.66 (3.1% above fair value)
No single metric tells the full story. See the BKK:MADAME stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Madame Bioscience PCL is engaged in the segments of the Packaging business, Food business, Retail sales of cosmetics, and Other businesses. Its activities include the manufacturing and selling of plastic packaging, restaurant business, advertising rental service in the gas station and manufacturing and selling of dried fruits, among others. The group derives a majority of its revenue from the Food business. The firm's product portfolio includes Ready meals, Frozen food, value-added seafood and vegetables, Flexible packaging, and PET Bottles.
21GF Score
Get the complete analysis for BKK:MADAME
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:MADAME has been successfully added to your 
